Dacheng Fund Tan Xiaogang: continue to plant fertile soil in China’s capital market and fully serve the direct financing needs of excellent enterprises

On the occasion of the opening of the year of the tiger, Tan Xiaogang, general manager of Dacheng Fund, issued a new year market outlook, pointing out that renyin year of the tiger will be full of confidence and hope, adhere to long-term ism, not afraid of short-term market fluctuations, adhere to the right path and do difficult and correct things. In the future, Dacheng Fund will continue to be deeply rooted in the fertile land of China’s capital market and fully serve the direct financing needs of excellent enterprises, residents’ wealth management needs and the reform and development needs of the capital market.

Tan Xiaogang pointed out that in the past year of the Xin Chou ox, China’s epidemic prevention and control has been solid and effective, creating a safe and stable development environment for all undertakings. China’s economy has gradually recovered, the capital market has made steady progress, and the development of the public fund industry has reached a new level. In this year, the yield of public offering partial stock funds exceeded 10%, significantly exceeding the main indexes, and the cumulative net profit of public offering funds was 720 billion yuan. In the past 24 years, the public funds have created a total profit of 6 trillion yuan and a total dividend of 1.7 trillion yuan for the holders, making an important contribution to the appreciation of residents’ wealth.

With the vigorous development momentum of the industry, Tan Xiaogang pointed out that the total management scale, public offering scale and institutional special account management scale of Dacheng Fund reached a record high in 2021, the average return rate of equity funds was 25.81%, the overall investment performance ranked among the top 10 fund companies in the whole market, the return rate of 31 products doubled in three years and that of 7 products doubled in three years, The yield of three equity funds ranked among the top ten in the industry, and the total scale of equity asset management reached 164.3 billion yuan. In addition, the number of customers reached 33 million, an increase of 7.5 million in a single year.

Looking forward to 2022, Tan Xiaogang pointed out that he believed in the strength of the market and was full of confidence and hope for the year of the tiger. In recent years, capital market reform has been unprecedented, policy support has been unprecedented, measures to improve the quality of listed companies have been carried out successively, and the market foundation has been continuously consolidated. Marked by the opening of the Beijing stock exchange, the multi-level capital market has been continuously improved, and the reform of the registration system has been carried out in an all-round way, continuously injecting fresh water into the market. The interconnection mechanism has been continuously improved, the proportion of A-share international index has been increasing, and the international positioning of China’s capital market has been significantly improved.

Tan Xiaogang pointed out that the investment and value-added ability of the industry will continue to be promoted, and the investment and value-added ability of the industry will continue to be improved side by side. “China has the world’s largest market and the richest intellectual resources. Its macro-economy is full of tenacity, and its micro industrial competitiveness continues to improve. In particular, the engineer dividend is replacing the demographic dividend as the biggest driving force for economic growth, and a large number of innovative enterprises are accelerating to emerge. This is one of our deepest feelings about investing in the front line. In the future, Dacheng Fund will continue to adhere to the price Value investment concept, take enterprise value as the criterion, timely update iterative research methods and valuation system, actively pay attention to the development of new technologies, Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) , new business forms and new models, focus on advanced manufacturing, scientific and technological innovation, carbon neutralization and consumption upgrading, accompany excellent enterprises to grow together and serve the high-quality development of China’s economy. “

- Advertisment -